Alumis (ALMS) and ACELYRIN (SLRN) to Merge

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. GPRK
6. SCHW
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to Alumis (ALMS) and ACELYRIN (SLRN) to Merge

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

February 6, 2025 4:15 PM EST

Topline data from Phase 3 ONWARD trials for Alumis ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026

Evaluation underway of development plan for ACELYRINs lonigutamab to confirm differentiation in a capital efficient manner

Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio

Alumis and ACELYRIN stockholders to own ~55% and ~45%,... More